GO
Loading...

AEterna Zentaris Inc

More

  • *FDA says not enough "verifiable" data, asks for fresh trial. *FDA says drug could have led to a cardiac event in trial. Nov 6- Canada's Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the drugmaker had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency.

  • Nov 6- Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the company had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency. An analysis showed the company's key trial did not meet its main efficacy goal, the FDA said, noting the lack of "complete and verifiable" data used...

  • FDA rejects Aeterna's growth hormone diagnostic test Thursday, 6 Nov 2014 | 7:34 AM ET

    Nov 6- Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, an experimental test designed to determine if adults' pituitary glands are secreting enough growth hormone. The company's trial did not meet its main goal, the FDA said, also noting the lack of "complete and verifiable" source data used to determine if adult patients were...

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Oct 12- AEterna Zentaris Inc:. *Announces pricing of US $16.5 million public offering of common shares and. *Says public offering of 6.6 million units priced at $2.50/ unit.

  • Aeterna Zentaris starts $15M stock offering Friday, 12 Oct 2012 | 12:25 AM ET

    NEW YORK-- Canadian drugmaker Aeterna Zentaris Inc. said Friday it is selling 6.6 million units of stock and warrants to raise money for product development. Shares of Aeterna Zentaris lost 73 cents, or 23.4 percent, to $2.39 in midday trading.

  • Aeterna Zentaris plans reverse stock split Wednesday, 3 Oct 2012 | 11:26 AM ET

    NEW YORK-- Canadian drugmaker Aeterna Zentaris Inc. said Wednesday that it will conduct a six-for-one reverse stock split to boost its share price and regain compliance with Nasdaq rules.

  • Oct 3- AEterna Zentaris Inc:. *Announces share consolidation to regain NASDAQ compliance. basis on October 5, 2012.

  • ASCO 2012 Stocks: Winners and Losers Monday, 4 Jun 2012 | 1:07 PM ET

    Here are some snap biotech and drug stock judgments after a weekend spent at the American Society of Clinical Oncology annual meeting.

  • Keryx Rises With Hopes About Cancer Drug Tuesday, 6 Mar 2012 | 6:20 AM ET

    The bulls were all over Keryx Biopharmaceuticals and AEterna Zentaris Monday amid optimism about their Perifosine drug.